Skip to main content

Table 1 Patient characteristics*

From: Rates of asthma attacks in patients with previously inadequately controlled mild asthma treated in clinical practice with combination drug therapy: an exploratory post-hoc analysis

  ICS/MON ICS/LABA/MON All Patients
Patient N (%) 181 (52.6%) 163 (47.4%) 344 (100.0%)
Years of age‡ 30.4 ± 9.3 32.6 ± 9.4 31.5 ± 9.4
Male sex 82 (45.3%) 69 (42.6%) 151 (44.0%)
Current smoker 6 (3.3%) 10 (6.1%) 16 (4.7%)
Years since asthma diagnosed 8.5 ± 7.6 8.0 ± 7.7 8.3 ± 7.7
Years since allergic rhinitis diagnosed‡ 10.7 ± 8.2 8.4 ± 7.7 9.6 ± 8.1
Allergic rhinitis severity    
   Mild intermittent 60 (33.2%) 64 (39.3%) 124 (36.1%)
   Mild persistent 87 (48.1%) 74 (45.4%) 161 (46.8%)
   Moderate-severe intermittent 26 (14.4%) 15 (9.2%) 41 (11.9%)
   Moderate-severe persistent 8 (4.4%) 10 (6.1%) 18 (5.2%)
Months on therapy in prior 12 months    
   ICS‡ 10.5 ± 3.4 11.2 ± 2.4 10.8 ± 3.0
   ICS/LABA‡ 1.1 ± 3.2 8.0 ± 5.2 4.4 ± 5.5
Asthma- and allergic rhinitis-related medical resource use in prior 12 months    
   Short-acting beta-agonist 155 (85.6%) 130 (79.8%) 285 (82.9%)
   Oral corticosteroids 21 (11.6%) 24 (14.7%) 45 (13.1%)
   Antibiotics 38 (21.0%) 44 (27.0%) 82 (23.8%)
   Antihistamines 129 (71.3%) 104 (63.8%) 233 (67.7%)
   Allergist visit‡ 85 (47.0%) 54 (33.1%) 139 (40.4%)
   Pulmonologist visit 1 (0.6%) 1 (0.6%) 2 (0.6%)
   Emergency Room visit 34 (18.8%) 23 (14.1%) 57 (16.6%)
   Hospitalization 7 (3.9%) 3 (1.8%) 10 (2.9%)
   Asthma attack† 49 (27.1%) 44 (27.0%) 93 (27.0%)
Months on therapy in 12-month follow-up‡ 10.5 ± 2.9 11.4 ± 1.9 10.9 ± 2.5
  1. *Values represent patient N (%) or mean ± SD. † An asthma attack was defined as use of an oral corticosteroid, an asthma-related ER visit, or an asthma-related hospitalization. ‡ p < 0.05 for ICS/MON compared with ICS/LABA/MON.